Tulsa, OK, September 23, 2013 –(PR.com)– Emerge Diagnostics is pleased to announce that it has received the 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its wireless device, PMRU-S.

The new clearance will allow for expansion of the EFA technology. The wireless ability will streamline the assessment process as well as create other efficiencies with its advanced capabilities.

“Emerge has set the industry standard for soft tissue diagnostics. Our wireless technology will bring an unprecedented level of innovation to this industry. This is a major milestone for Emerge Diagnostics,” said Jerry W. Wilkins, CEO of Emerge Diagnostics.

About Emerge Diagnostics

Emerge Diagnostics is the provider of the Electrodiagnostic Functional Assessment, EFA and EFA–STM©. The EFA–Soft Tissue Management (EFA–STM) program is a bookend solution that compares pre and post-loss data and is a recommended best practice to accurately distinguish compensable workplace injuries and/or exacerbation of pre-existing injuries from chronic, unrelated conditions. In addition, employees receive better treatment for compensable conditions. For more about Emerge Diagnostics, please visit our website at www.emergedx.com.